Clinical setback in lung cancer for key Chi-Med project
This article was originally published in Scrip
Hutchison China MediTech(Chi-Med) has put the clinical development of one of its most advanced pipeline projects on hold after an interim analysis of data from a Chinese Phase II study showed it to have missed an efficacy endpoint.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.